NuSep Announces Successful Phase 1 Clinical Trial for Rapid IVF
Sperm Separation Device to assist infertile couples
(sz) NuSep (ASX: NSP), a publicly listed company based in Australia and the United States with a 30 year heritage in biological separations, today unveiled the IVF sperm separation device, the SpermSep CS10.
The SpermSep uses an electrical field to separate normal sperm from damaged sperm. SpermSep has the potential to increase the success rate of Assisted Reproductive Technology (ART) treatments.
“We are extremely excited to announce these results from this revolutionary new device. Male infertility is a factor for more than 40% of infertile couples. The SpermSep rapidly (5 minutes) isolates normal healthy sperm from DNA damaged sperm providing renewed hope for couples who have previously struggled to conceive a child,” said John Manusu, Managing Director of NuSep.
“A clinical trial of the SpermSep has recently concluded at Westmead Fertility Centre, Sydney. Three out of nine women who had sperm prepared with the SpermSep became pregnant and there have been two live births to date. This compared very favorably with treatment using the current technology,” he added.
Developed together with Professor John Aitken from the University of Newcastle, the device works on the principle that sperm with the most negatively charged membranes are likely to have the least DNA damage. The SpermSep is a consecutive processing, single use product which eliminates the potential for sample mix-up a potential problem with the existing process. more…
From: »The Sydney Morning Herald«